Cargando…
EphB4 as a therapeutic target in mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. A search for novel targets and therapeutics is underway, and rece...
Autores principales: | Liu, Ren, Ferguson, Benjamin D, Zhou, Yue, Naga, Kranthi, Salgia, Ravi, Gill, Parkash S, Krasnoperov, Valery |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671960/ https://www.ncbi.nlm.nih.gov/pubmed/23721559 http://dx.doi.org/10.1186/1471-2407-13-269 |
Ejemplares similares
-
The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder
por: Li, Xiuqing, et al.
Publicado: (2014) -
The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
por: Ferguson, Benjamin D., et al.
Publicado: (2013) -
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma
por: Randolph, Matthew E., et al.
Publicado: (2017) -
Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
por: Djokovic, Dusan, et al.
Publicado: (2010) -
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas
por: Bhatia, Shilpa, et al.
Publicado: (2016)